Aims/hypothesis Obesity is characterised by lipid accumulation in skeletal muscle, which increases the risk of developing insulin resistance and type 2 diabetes. AMP-activated protein kinase (AMPK) is a sensor of cellular energy status and is activated in skeletal muscle by exercise, hormones (leptin, adiponectin, IL-6) and pharmacological agents (5-amino-4-imidazolecarboxamide ribonucleoside [AICAR] and metformin). Phosphorylation of acetyl-CoA carboxylase 2 (ACC2) at S221 (S212 in mice) by AMPK reduces ACC activity and malonyl-CoA content but the importance of the AMPK-ACC2-malonyl-CoA pathway in controlling fatty acid metabolism and insulin sensitivity is not understood; therefore, we characterised Acc2 S212A knock-in (ACC2 KI) mice. Methods Whole-body and skeletal muscle fatty acid oxidation and insulin sensitivity were assessed in ACC2 KI mice and wild-type littermates.
Introduction
Skeletal muscle is the major site of insulin-stimulated glucose disposal (∼80%); therefore, metabolic perturbations in this tissue have an important influence on whole-body glucose homeostasis. AMP-activated protein kinase (AMPK) is an evolutionarily conserved metabolic stress-sensing kinase that regulates cellular energy status by phosphorylating key substrates [1] . Consistent with its role as an energy sensor, skeletal muscle AMPK is rapidly activated in response to exercise and hormones, an effect associated with increases in fatty acid oxidation [2] . Fatty acid oxidation in skeletal muscle is regulated by carnitine palmitoyl transferase (CPT-I), which mediates the transport of long-chain fatty acids across the outer mitochondrial membrane by binding them to carnitine. CPT-I activity is inhibited by malonyl-CoA, which is produced following carboxylation of acetyl-CoA by acetyl-CoA carboxylase (ACC). ACC exists as two isoforms, ACC1 and ACC2 [3] . Liver, brown and white adipose and the brain contain predominantly ACC1 with low amounts of ACC2, while skeletal and cardiac muscles contain almost exclusively ACC2 [3, 4] . ACC1 and ACC2 are distinguished by an N-terminal extension of 146 amino acids in ACC2 that is thought to localise this isoform to the outer mitochondrial membrane [5] thus facilitating the regulation of fatty acid oxidation by malonyl-CoA inhibition of CPT-I. Initial reports that ACC2 null (knockout [KO]) mice had accelerated fatty acid oxidation and enhanced insulin sensitivity appeared to fit with ACC2 having an important role in regulating insulin sensitivity [6, 7] . However, two independent reports have recently questioned these findings: Hoehn et al [8] and Olson et al [9] found no change in body mass or insulin sensitivity of whole-body and skeletal muscle-specific ACC2 KO mice, respectively. Thus the role of ACC2 in controlling body mass and adiposity, skeletal muscle fatty acid oxidation and insulin sensitivity is currently unclear.
Genetic mouse models have been utilised to better understand the role of AMPK in controlling skeletal muscle fatty acid oxidation. Studies in Ampk whole-body α2 and β2 KO, skeletal muscle-specific α2 kinase dead (KD) and skeletal muscle-specific Ampk β1β2 KO (AMPK β1β2 M-KO) mice, which all have dramatic reductions in skeletal muscle AMPK activity, have found that fatty acid oxidation is not impaired [10] [11] [12] [13] . A caveat of these models is that a small degree of ACC phosphorylation is still present, which may be sufficient to inhibit ACC activity and increase fatty acid oxidation. However, changes in substrate use cannot be viewed in isolation because AMPK has multiple substrates that have an impact on carbohydrate and fatty acid metabolism [1] . In addition, compensatory regulation of AMPK-independent pathways, like those involving sirtuin 1 and tre-1/USP6, BUB2, cdc 16 domain family member 1 (TBC1D1) could increase fatty acid oxidation [14] .
To alleviate these concerns we have recently characterised mice harbouring targeted knock-in (Ser-Ala) mutations at both S79 and S212 AMPK phosphorylation sites on ACC1 and ACC2, respectively (named Acc double knock-in mice [ACC DKI]) [15] . Tissues from ACC DKI mice have increased ACC activity and malonyl-CoA, increased rates of liver lipogenesis and reduced fatty acid oxidation, contributing to a fatty liver. ACC DKI mice also have reduced rates of skeletal muscle fatty acid oxidation and develop modest impairments in muscle insulin sensitivity. Despite these data indicating that AMPK phosphorylation of both ACC1 and ACC2 is critical for controlling insulin sensitivity, the importance of the ACC2 isoform in controlling whole-body or skeletal muscle fatty acid oxidation and insulin sensitivity has not been tested. This is especially relevant for a number of reasons: (1) there are discrepancies regarding the importance of ACC2 in controlling skeletal muscle insulin sensitivity [6] [7] [8] [9] ; (2) ACC1 may be able to compensate for ACC2 function in the control of skeletal muscle fatty acid oxidation [9] ; (3) it is not currently known whether pharmacological activators of AMPK that increase skeletal muscle fatty acid oxidation (e.g. 5-amino-4-imidazolecarboxamide ribonucleoside [AICAR]) mediate their effects through the AMPK-ACC signalling pathway.
To specifically assess the contribution of ACC2 S212 phosphorylation in regulating fatty acid oxidation and insulin sensitivity we characterised Acc2 S212A KI (ACC2 KI) mice.
We found that ACC2 KI mice tended to have reduced fatty acid oxidation rates in skeletal muscle and, importantly, this was not increased by AICAR treatment. Consistent with these findings ACC2 KI mice fed a control chow diet had increased lipid deposition in skeletal muscle and developed insulin resistance, suggesting that ACC2 S212 phosphorylation is required for the maintenance of not only skeletal muscle lipid homeostasis but also glucose metabolism in lean healthy mice. However, on an obesity-promoting high-fat diet (HFD) ACC2 KI mice were indistinguishable from their wild-type (WT) littermates suggesting that the HFD overwhelmed the genotype differences observed in chow-fed mice.
Methods
Animal experiments ACC2 KI mice were generated and housed as described [15] . Male mice at 6 weeks of age were maintained on a chow diet (17% kJ fat; diet 8640, Harlan Teklad, Madison, WI, USA) or an HFD (SF04-027; Specialty Feeds, Perth, WA, Australia) for 12 weeks and had free access to food and water. All animal procedures were approved by the St Vincent's Hospital Animal Ethics Committee and McMaster University Animal Ethics Committee. Fed and overnight-fasted (12 h) blood was collected via submandibular bleed and serum was stored at −80°C before analyses [12] .
Basal metabolism cage experiments and the calculation of substrate utilisation were performed as described [12, 16] . Palmitate oxidation was measured in isolated extensor digitorum longus (EDL) muscle, with or without AICAR (2 mmol/l) [10] . Hyperinsulinaemic-euglycaemic clamps were performed as described [15, 17] . 2-Deoxyglucose (2DG) uptake was determined in isolated soleus and EDL muscles treated with vehicle or submaximal concentration of insulin (400 μU/ml). See electronic supplementary material (ESM) Methods for details.
Analytical methods For western blotting, muscle lysates were prepared and antibodies used as described. The mRNA expression of Acc1, Acc2, Tnf, Il1b, Il6, Kc (also known as Cxcl1), Ccl2 and Il10 was determined in quadriceps muscle. Adipocyte size was determined in white epididymal adipose sections that had been fixed in formalin, embedded in paraffin and stained with haematoxylin and eosin [18] . Citrate synthase activity was determined as described. The activity of succinate dehydrogenase and cytochrome (cyt) c oxidase and the assessment of fibre-type distribution were performed as described in the ESM Methods. Muscle glycogen content was determined as glycosyl units after acid hydrolysis [19] . Triacylglycerol (TAG) was extracted [20] and lipidomics performed. To determine the sensitivity of CPT-I to malonylCoA, saponin permeabilised fibres were prepared as described [21, 22] . See ESM Methods for details.
Statistics Unless otherwise noted, data were expressed as means ± SEM. Results were analysed using Student's t test, paired t test or ANOVA procedures, where appropriate, using GraphPad Prism version 5.01 for Windows, GraphPad Software, La Jolla, CA, USA, www.graphpad.com. Significance was accepted at p<0.05.
Results
ACC2 S212 phosphorylation is required for controlling muscle fatty acid oxidation in response to AICAR ACC2 KI mice had no detectable ACC2 S212 phosphorylation either basally or following treatment with AICAR, confirming successful S212 mutation in ACC2 KI mice and that ACC2 is the only detectable ACC isoform present in skeletal muscle (Fig. 1a) . The ACC2 KI mutation did not alter Acc1 or Acc2 mRNA expression, ACC1 or ACC2 protein expression (ESM Fig. 1a , b) or AMPK α2 activity (Fig. 1b) . Malonyl-CoA decarboxylase, which plays a reciprocal role to ACC in the regulation of malonyl-CoA production [23] [24] [25] and is downregulated in ACC2 M-KO mice [9] , was unchanged in skeletal muscle of ACC2 KI mice (ESM Fig. 1c) .
We next measured fatty acid oxidation in skeletal muscle from WT and ACC2 KI mice treated with or without 2 mmol/l AICAR. Fatty acid oxidation tended to be lower in isolated EDL muscles from ACC2 KI mice (−24%; p<0.06) and was increased in isolated EDL muscles from WT but not ACC2 KI mice in response to AICAR (Fig. 1c) . These data highlight the importance of ACC2 S212 phosphorylation in controlling skeletal muscle fatty acid oxidation with the pharmacological AMPK activator AICAR. To investigate whether these differences in muscle fatty acid oxidation have an impact on wholebody rates of substrate use we completed experiments in metabolic cages wherein mice were injected with either saline or AICAR. There was no significant difference in oxygen consumption (VO 2 ) or CO 2 production (VCO 2 ) between genotypes or treatments; however, the respiratory quotient (RQ) was significantly reduced in WT but not ACC2 KI mice (ESM Table 1 ). The drop in RQ indicates a greater reliance on fatty acid substrates in WT but not ACC2 KI mice following AICAR injection (Fig. 1d) , a finding consistent with changes in ACC phosphorylation (Fig. 1e ). These data indicate that pharmacological activation of AMPK by AICAR increases whole-body rates of fatty acid oxidation through the phosphorylation of ACC2 S212.
ACC2 KI mice have normal appetite and energy expenditure and do not develop obesity when fed a control chow diet We found that at 18 weeks of age body mass, adiposity and adipocyte size were comparable between WT and ACC2 KI mice (Fig. 2a, b) . Similarly, oxygen consumption, activity levels and food intake were not altered in ACC2 KI mice ( Table 1 ), indicating that phosphorylation of ACC2 is not critical for controlling whole-body energy expenditure or intake.
ACC2 S212 phosphorylation is required for preventing ectopic lipid accumulation in skeletal muscle Despite similar adiposity, body mass and energy expenditure, modest changes in skeletal muscle fatty acid oxidation would be anticipated to alter skeletal muscle lipid levels over time. Consistent with this hypothesis, we found that ACC2 KI mice had a 76% increase in skeletal muscle TAG (Fig. 2c ). There were no differences in liver TAG (Fig. 2c) , which is reliant on both ACC1 S79 and ACC2 S212 phosphorylation [15] . Muscle lipidomics found that this increase was not confined to TAG, as C16:0, C18:0 and C20:0 ceramides were also increased in ACC2 KI muscle (Fig. 2d) . Consistent with a shift towards lower rates of skeletal muscle fatty acid oxidation, ACC2 KI mice had reduced muscle glycogen, indicative of a greater reliance on carbohydrate oxidation (Fig. 2e) , whereas liver glycogen was not changed (Fig. 2e ). These data demonstrate that ACC2 S212 phosphorylation is essential for maintaining skeletal muscle lipid homeostasis.
Lack of ACC2 S212 phosphorylation does not adversely alter mitochondrial function in skeletal muscle Mitochondrial dysfunction or reduced mitochondrial biogenesis and density can also lead to a decrease in fatty acid oxidation and subsequent accumulation of bioactive lipids including ceramides [26] ; therefore, we assessed these variables. We found that citrate synthase and succinate dehydrogenase activity, and expression of proteins involved in oxidative phosphorylation (OXPHOS), were not different in ACC2 KI mice (Fig. 3a-e) . This was despite an increase in cyt c oxidase activity and a modest oxidative fibre-type shift (type IIb to type a/x myosin heavy chain isoforms) (Fig. 3f, g ). In addition, maximal mitochondrial respiratory chain complex function was normal in the presence of various substrates, including palmitoylCoA and palmitate (Fig. 3h) , indicating that mitochondrial function was intact. Altered CPT-I sensitivity to malonyl-CoA has been reported [27] [28] [29] but there was no difference in palmitoyl-CoA respiration rates and IC 50 for malonyl-CoA between permeabilised muscle fibres of WT and ACC2 KI mice (Fig. 4) . Collectively these data indicate that the ACC2 KI mutation results in reduced fatty acid oxidation rates independent of intrinsic changes in mitochondrial function.
ACC2 S212 phosphorylation is required for the maintenance of skeletal muscle insulin sensitivity Elevated skeletal muscle ceramides can contribute to the development of insulin resistance [30] . ACC2 KI mice had fasting hyperinsulinaemia (Fig. 5a ) and developed modest whole-body glucose and insulin intolerance (Fig. 5b, c) . We subsequently performed hyperinsulinaemic-euglycaemic clamps (ESM Table 2 ). During the clamp ACC2 KI mice had a lower glucose infusion rate (GINF) (Fig. 5d ) and this was due to a reduced glucose disposal rate (GDR) (Fig. 5e ). Hepatic glucose production and per cent suppression of hepatic glucose production were not altered indicating that ACC2 KI mice had normal liver insulin sensitivity (ESM Table 2 ). Serum insulin during the clamp was similar between genotypes (ESM Table 2 ). To examine whether adipose tissue or skeletal muscle contributed to impaired insulin-stimulated GDR we measured insulin-stimulated 2DG clearance following the clamp and found that ACC2 KI mice had a strong tendency for reduced skeletal muscle 2DG clearance (p=0.06, Fig. 5f ). There was no difference in adipose tissue 2DG clearance (ESM Table 2 ). Similar observations of reduced insulin-stimulated glucose uptake were observed in soleus and EDL muscles isolated from ACC2 KI mice and treated with insulin ex vivo suggesting that the defect in insulin action was intrinsic to skeletal muscle and not due to a change in circulating factors (Fig. 5g) . These data indicate that ACC2 S212 phosphorylation is important for preventing insulin resistance in skeletal muscle but not liver or adipose tissue. To investigate the mechanisms contributing to skeletal muscle insulin resistance in ACC2 KI mice we examined insulin-signal transduction. We found that, consistent with recent reports indicating that ceramide-induced insulin resistance in skeletal muscle is downstream of canonical insulin signalling [31] , Akt and TBC1D4/TBC1D1 phosphorylation were unaltered in insulin-stimulated muscles (gastrocnemius muscle following the clamp and isolated soleus and EDL muscles treated with or without 400 μU/ml insulin) of ACC2 KI mice compared with WT controls (Fig. 6a-d) . Reduced muscle insulin sensitivity in ACC2 KI mice also appeared to be independent of changes in GLUT4 expression and muscle inflammation (Fig. 6e, f) . These data suggest that control of muscle insulin resistance is likely downstream of TBC1D4 and may involve plasma membrane remodelling and GLUT4 trafficking as proposed [32] . ACC2 S212 phosphorylation does not exacerbate the development of HFD-induced obesity or insulin resistance We also examined the effects of an HFD and found that after 12 weeks WT and ACC2 KI mice had increased body mass and adiposity as well as increased serum leptin levels compared with chow-fed controls but there were no differences between genotypes ( Fig. 7a and ESM Table 3 ). We found that while, as expected, the HFD reduced the RQ compared with chow controls there were no differences between genotypes indicating that ACC2 phosphorylation is not required for the upregulation of fatty acid oxidation in response to increased substrate availability (Table 1 ). There were also no genotypic differences in food intake, activity levels or oxygen consumption (Table 1) . In contrast to the genotype effect observed in chow-fed mice, there were no differences in serum insulin or NEFA between WT and ACC2 KI mice fed an HFD (Fig. 7b) . Similarly, neither insulin sensitivity nor glucose tolerance was different between ACC2 KI and WT mice on an HFD (Fig. 7c, d ). Consistent with comparable insulin sensitivity when fed the HFD, we found that skeletal muscle TAG and insulin-stimulated glucose uptake were comparable between genotypes (Fig. 7e, f) .
Discussion
ACC1 and ACC2 have distinct structures as well as cellular and tissue specific localisation but our understanding of their enzymatic control is almost entirely based on studies involving ACC1 [33] [34] [35] [36] . With the discovery of ACC2 and its primary localisation to the outer mitochondrial membrane in skeletal muscle [5] , it was assumed that phosphorylation of ACC2 S212 by AMPK regulated enzyme activity in a manner similar to ACC1 and that this may be important for controlling skeletal muscle fatty acid oxidation. While associations between AICAR-stimulated ACC2 phosphorylation and fatty acid oxidation have been reported [8, 10, [37] [38] [39] , in the current study we provide direct genetic evidence establishing that AICAR-induced increases in fatty acid oxidation are dependent on ACC2 S212 phosphorylation (Fig. 1) . Importantly, the phenotypic differences in fatty acid oxidation indicate that ACC2 S212 phosphorylation is the primary point of AMPK regulation of skeletal muscle fatty acid oxidation.
The phosphorylation of ACC2 S212 is increased in skeletal muscle in response to multiple circulating hormones that increase fatty acid oxidation, reduce obesity and improve insulin sensitivity (for review see [40] ); therefore, we hypothesised that ACC2 KI mice might develop obesity and insulin resistance. However, ACC2 KI mice did not become obese despite having reduced rates of fatty acid oxidation in skeletal muscle. An important aspect of our study is that while resting muscle contributes ∼20% to whole-body resting energy expenditure we did not detect differences in the RQ of ACC2 KI mice. We have found that the ACC2 KI mutation on its own does not have an impact on fatty acid oxidation in tissues expressing the ACC1 isoform, such as the liver [15] ; therefore, detecting small reductions in basal fatty acid oxidation (∼15%) in muscle of the ACC2 KI mice would involve detecting a 2-3% change in RQ, which is likely below the limits of detection of indirect calorimetry. Importantly, even if there was a detectable reduction in whole-body rates of fatty acid oxidation, this would not be sufficient to promote the development of obesity without a decrease in whole-body energy expenditure as previously described [8] .
We found that reduction in skeletal muscle fatty acid oxidation was associated with an increase in muscle TAG, equivalent to that in an obese mouse fed an HFD for 12 weeks. In contrast, ACC2 KI mice had normal levels of liver lipids. It is now well accepted that intramuscular TAG is unlikely to cause insulin resistance, but instead serves as a protective mechanism to sequester reactive lipids [41, 42] . Rather, spillover from the intramuscular TAG pool into ceramides plays an import role in the development of skeletal muscle insulin resistance [43] [44] [45] as ceramides compromise membrane dynamics resulting in improper GLUT4 insertion. In agreement with these findings, ACC2 KI mice had elevated skeletal muscle ceramides, which was associated with skeletal muscle insulin resistance that was independent of defects in insulinsignal transduction, GLUT4 expression and muscle inflammation. This is consistent with recent reports demonstrating that control of lipid-induced insulin resistance is downstream of TBC1D4 signalling and may involve actin remodelling [31, 32] . Consistent with the development of skeletal muscle insulin resistance, ACC2 KI mice also developed whole-body hyperinsulinaemia and impaired whole-body glucose tolerance and insulin sensitivity. So a key question is what was the source of substrate that ACC2 KI mice were using in order to provide energy if both fatty acid oxidation and insulinstimulated glucose uptake were reduced? We speculate that under conditions of reduced glucose uptake and reduced fatty acid oxidation most of the glucose that is taken up is channelled to oxidation, leaving less available for storage as glycogen. This idea is supported by lower glycogen levels in skeletal muscle of ACC2 KI mice.
We also assessed insulin sensitivity in ACC2 KI mice when metabolically challenged with an HFD for 12 weeks. Interestingly, the ACC2 KI mutation had no effect on insulin sensitivity when mice were fed the HFD. This may be due to reduced muscle AMPK and ACC phosphorylation, which is common in obese mice [46] and would in turn be expected to minimise the genotype differences. Additionally, it is known that pyruvate dehydrogenase kinase 4, a key enzyme involved in switching glucose to fatty acid oxidation by inhibiting pyruvate dehydrogenase activity (and glucose oxidation) p<0.001 vs basal, same genotype [47] , is upregulated in response to an HFD [48, 49] . Further studies investigating AMPK-ACC2-independent mechanisms regulating fatty acid oxidation under high fatty acid availability are warranted.
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